Plug and Play Seattle picks 11 startups for 4th cohort, from space robotics to biotech
Plug and Play Seattle selected 11 startups for the fourth cohort of its accelerator program, with 10 of the companies based in Seattle. The group includes several life sciences startups, including CounterX Therapeutics, DiffBio, Q-Immune and Talus Bio, working across antibody therapeutics, protein design, cell therapy and drug discovery.
The 12-week program will include virtual and in-person programming at the University of Washington’s CoMotion Labs and the SNBL Global Gateway in Everett. Plug and Play Seattle Director Jack Callaghan pointed to the region’s “talent and research depth” as a foundation for companies working across areas including drug discovery and AI.
With nearly the entire cohort based in Seattle, the program reflects the range of early-stage companies continuing to develop in the region and the local resources available to help them grow.